N J Meropol

927 total citations
21 papers, 774 citations indexed

About

N J Meropol is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, N J Meropol has authored 21 papers receiving a total of 774 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in N J Meropol's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Mechanisms and Therapy (2 papers). N J Meropol is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Mechanisms and Therapy (2 papers). N J Meropol collaborates with scholars based in United States and United Kingdom. N J Meropol's co-authors include Lynn M. Schuchter, P J O’Dwyer, Paul J. Catalano, David T. Levy, Bruce J. Giantonio, Al B. Benson, Patrick J. Creaven, Edward L. Korn, Leonard E. Braitman and M MacDermott and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

N J Meropol

21 papers receiving 752 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N J Meropol United States 13 479 257 214 140 94 21 774
Ernest Marshall United Kingdom 17 482 1.0× 209 0.8× 287 1.3× 232 1.7× 40 0.4× 42 938
Meredith K. Chuk United States 14 429 0.9× 133 0.5× 175 0.8× 260 1.9× 57 0.6× 29 858
Phillip Periman United States 13 293 0.6× 254 1.0× 147 0.7× 180 1.3× 112 1.2× 26 693
Troy Z. Horvat United States 8 966 2.0× 312 1.2× 252 1.2× 231 1.6× 62 0.7× 18 1.2k
J. H. Doroshow United States 14 247 0.5× 99 0.4× 187 0.9× 67 0.5× 68 0.7× 30 543
Jeffrey Schneider United States 15 592 1.2× 126 0.5× 132 0.6× 160 1.1× 120 1.3× 40 882
B. Rovati Italy 16 318 0.7× 265 1.0× 219 1.0× 76 0.5× 36 0.4× 38 651
Prakash Kharel United States 6 739 1.5× 342 1.3× 249 1.2× 205 1.5× 60 0.6× 13 1.0k
Sebastian Belle Germany 17 455 0.9× 103 0.4× 206 1.0× 219 1.6× 255 2.7× 65 852
Carla M. van Herpen Netherlands 14 325 0.7× 113 0.4× 195 0.9× 146 1.0× 98 1.0× 27 608

Countries citing papers authored by N J Meropol

Since Specialization
Citations

This map shows the geographic impact of N J Meropol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N J Meropol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N J Meropol more than expected).

Fields of papers citing papers by N J Meropol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N J Meropol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N J Meropol. The network helps show where N J Meropol may publish in the future.

Co-authorship network of co-authors of N J Meropol

This figure shows the co-authorship network connecting the top 25 collaborators of N J Meropol. A scholar is included among the top collaborators of N J Meropol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N J Meropol. N J Meropol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Cáceres, Inmaculada Ibañez de, et al.. (2004). Telomerase is Frequently Activated in Tumors with Microsatellite Instability. Cancer Biology & Therapy. 3(3). 289–292. 8 indexed citations
5.
Tolcher, A. W., Amita Patnaik, Eric K. Rowinsky, et al.. (2004). A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3060–3060. 22 indexed citations
6.
Tolcher, A. W., Amita Patnaik, Eric K. Rowinsky, et al.. (2004). A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3060–3060. 10 indexed citations
7.
Mehren, Margaret von, Philip M. Arlen, James L. Gulley, et al.. (2001). The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.. PubMed. 7(5). 1181–91. 138 indexed citations
8.
Cheng, J., Bruce A. Werness, James S. Babb, & N J Meropol. (1999). Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma.. PubMed. 5(5). 1057–62. 38 indexed citations
9.
10.
Fehniger, Todd A., et al.. (1998). Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunology Immunotherapy. 46(6). 318–326. 74 indexed citations
11.
Schwartz, Gary N., Lakshmi Pendyala, Hedy L. Kindler, et al.. (1998). The clinical development of paclitaxel and the paclitaxel/carboplatin combination. European Journal of Cancer. 34(10). 1543–1548. 10 indexed citations
12.
Meropol, N J, et al.. (1997). Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.. PubMed. 11(9 Suppl 10). 22–5. 5 indexed citations
13.
Vaughn, David J., N J Meropol, Christopher P. Holroyde, et al.. (1997). A Phase II Study of 5-Fluorouracil, Leucovorin, Adriamycin, and Cisplatin (FLAP) for Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. American Journal of Clinical Oncology. 20(3). 242–246. 6 indexed citations
14.
Meropol, N J, et al.. (1997). Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.. Journal of Clinical Oncology. 15(2). 766–772. 15 indexed citations
15.
Meropol, N J, et al.. (1996). Diabetes mellitus induced by low-dose interleukin-2. Cancer Immunology Immunotherapy. 43(1). 59–62. 8 indexed citations
16.
Meropol, N J, Michelle M. Porter, Leslie E. Blumenson, et al.. (1996). Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.. PubMed. 2(4). 669–77. 58 indexed citations
17.
Cunningham, David, John Zalcberg, I E Smith, et al.. (1996). ‘Tomudex’ (ZD1694) : A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Annals of Oncology. 7(2). 179–182. 45 indexed citations
18.
Meropol, N J, Nicholas J. Petrelli, Miguel A. Rodrı́guez-Bigas, et al.. (1996). A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 37(6). 581–586. 56 indexed citations
19.
Meropol, N J, et al.. (1992). Severed Myelosuppression Resulting From Concurrent Administration of Granulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy. JNCI Journal of the National Cancer Institute. 84(15). 1201–1203. 78 indexed citations
20.
Schuchter, Lynn M., et al.. (1992). The current status of toxicity protectants in cancer therapy.. PubMed. 19(6). 742–51. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ernest Marshall Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by Phillip Periman Breakdown of academic impact, for papers by Troy Z. Horvat Breakdown of academic impact, for papers by J. H. Doroshow Breakdown of academic impact, for papers by Jeffrey Schneider Breakdown of academic impact, for papers by B. Rovati Breakdown of academic impact, for papers by Prakash Kharel Breakdown of academic impact, for papers by Sebastian Belle Breakdown of academic impact, for papers by Carla M. van Herpen
Rankless by CCL
2026